In this context, innovative nanomedical tools targeting the chemokine receptor CXCR4, show great promise in selectively eliminating receptor-overexpressing cancer cells, thereby limiting disease progression and tumor dissemination while minimizing side toxicities. This evidence concerns the gene CXCR4 and neoplasm.